Prognostic Significance of Tumor-Associated Macrophages in Chondroblastoma and Their Association with Response to Adjuvant Radiotherapy

References

• Tathe SP, Parate SN, Jaiswal KN, Randale AA. Intraoperative crush smear cytology of vertebral chondroblastoma: a diagnostic challenge. Diagn Cytopathol. 2018;46(1):79–82. doi:10.1002/dc.23799
   PubMed Web of Science ®Google Scholar
• Zheng BW, Huang W, Liu FS, et al. Clinicopathological and prognostic characteristics in spinal chondroblastomas: a pooled analysis of individual patient data from a single institute and 27 studies. Global Spine J. 2021:219256822110057. doi:10.1177/21925682211005732.
   Web of Science ®Google Scholar
• Chung OM, Yip SF, Ngan KC, Ng WF. Chondroblastoma of the lumbar spine with cauda equina syndrome. Spinal Cord. 2003;41(6):359–364. doi:10.1038/sj.sc.3101458
   PubMed Web of Science ®Google Scholar
• Angelini A, Hassani M, Mavrogenis AF, et al. Chondroblastoma in adult age. Eur J Orthop Surg Traumatol. 2017;27(6):843–849. doi:10.1007/s00590-017-1996-7
   PubMedGoogle Scholar
• Herget GW, Maier D, Südkamp NP, et al. Anatomical reconstruction of the acromion using an autologous iliac crest graft for treatment of recurrent chondroblastoma: a case report. JBJS Case Connect. 2019;9(3):e0086. doi:10.2106/JBJS.CC.19.00086
   PubMedGoogle Scholar
• Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33(3):119–126. doi:10.1016/j.it.2011.12.001
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Valilou SF, Soltani A, et al. Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol (Dordr). 2019;42(5):591–608. doi:10.1007/s13402-019-00453-z
   PubMed Web of Science ®Google Scholar
• Huang X, Pan Y, Ma J, et al. Prognostic significance of the infiltration of CD163(+) macrophages combined with CD66b(+) neutrophils in gastric cancer. Cancer Med. 2018;7(5):1731–1741. doi:10.1002/cam4.1420
   PubMed Web of Science ®Google Scholar
• Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22(1):38–51. doi:10.4048/jbc.2019.22.e5
   PubMed Web of Science ®Google Scholar
• Hu WM, Yang YZ, Zhang TZ, Qin CF, Li XN. LGALS3 is a poor prognostic factor in diffusely infiltrating gliomas and is closely correlated with cd163+ tumor-associated macrophages. Front Med (Lausanne). 2020;7:182. doi:10.3389/fmed.2020.00182
   PubMed Web of Science ®Google Scholar
• Rakaee M, Busund LR, Jamaly S, et al. Prognostic value of macrophage phenotypes in resectable non-small cell lung cancer assessed by multiplex immunohistochemistry. Neoplasia. 2019;21(3):282–293. doi:10.1016/j.neo.2019.01.005
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Miyata Y, Mochizuki Y, et al. Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma. Hum Pathol. 2018;79:102–108. doi:10.1016/j.humpath.2018.05.007
   PubMed Web of Science ®Google Scholar
• Yang C, Wei C, Wang S, et al. Elevated CD163(+)/CD68(+) ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer. Int J Biol Sci. 2019;15(5):984–998. doi:10.7150/ijbs.29836
   PubMed Web of Science ®Google Scholar
• Hwang I, Kim JW, Ylaya K, et al. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J Transl Med. 2020;18(1):443. doi:10.1186/s12967-020-02618-z
   PubMed Web of Science ®Google Scholar
• Lin PP, Thenappan A, Deavers MT, Lewis VO, Yasko AW. Treatment and prognosis of chondroblastoma. Clin Orthop Relat Res. 2005;NA(438):103–109. doi:10.1097/01.blo.0000179591.72844.c3
   Google Scholar
• Xu H, Nugent D, Monforte HL, et al. Chondroblastoma of bone in the extremities: a multicenter retrospective study. J Bone Joint Surg Am. 2015;97(11):925–931. doi:10.2106/JBJS.N.00992
   PubMedGoogle Scholar
• Konishi E, Nakashima Y, Mano M, et al. Chondroblastoma of extra-craniofacial bones: clinicopathological analyses of 103 cases. Pathol Int. 2017;67(10):495–502. doi:10.1111/pin.12586
   PubMed Web of Science ®Google Scholar
• Laitinen MK, Stevenson JD, Evans S, et al. Chondroblastoma in pelvis and extremities- a single centre study of 177 cases. J Bone Oncol. 2019;17:100248. doi:10.1016/j.jbo.2019.100248
   PubMed Web of Science ®Google Scholar
• Zou MX, Lv GH, Wang XB, et al. Clinical impact of the immune microenvironment in spinal chordoma: immunoscore as an independent favorable prognostic factor. Neurosurgery. 2019;84(6):E318–E333. doi:10.1093/neuros/nyy274
   PubMed Web of Science ®Google Scholar
• Fisher CG, Saravanja DD, Dvorak MF, et al. Surgical management of primary bone tumors of the spine: validation of an approach to enhance cure and reduce local recurrence. Spine (Phila Pa 1976). 2011;36(10):830–836. doi:10.1097/BRS.0b013e3181e502e5
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Zou MX, Zheng BW, Liu FS, et al. The relationship between tumor-stroma ratio, the immune microenvironment, and survival in patients with spinal chordoma. Neurosurgery. 2019;85(6):E1095–e1110. doi:10.1093/neuros/nyz333
   PubMed Web of Science ®Google Scholar
• Zou MX, Peng AB, Lv GH, et al. Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res. 2016;8(7):3274–3287.
   PubMed Web of Science ®Google Scholar
• Zou MX, Lv GH, Li J, et al. Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis. Am J Transl Res. 2016;8(2):516–529.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812–817. doi:10.1093/annonc/mdv009
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen K, Yang H, et al. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma. J Neurooncol. 2014;116(1):77–82. doi:10.1007/s11060-013-1274-4
   PubMed Web of Science ®Google Scholar
• Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4(5):419–430. doi:10.1158/2326-6066.CIR-15-0110
   PubMed Web of Science ®Google Scholar
• Zou MX, Pan Y, Huang W, et al. A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma. Clin Transl Med. 2020;10(1):224–237. doi:10.1002/ctm2.4
   PubMed Web of Science ®Google Scholar
• Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11):829–835. doi:10.1093/jnci/86.11.829
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–612. doi:10.1158/0008-5472.CAN-05-4005
   PubMed Web of Science ®Google Scholar
• Chen X, Chen J, Zhang W, et al. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget. 2017;8(68):112685–112696. doi:10.18632/oncotarget.22340
   PubMedGoogle Scholar
• Minami K, Hiwatashi K, Ueno S, et al. Prognostic significance of CD68, CD163 and folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med. 2018;15(5):4465–4476. doi:10.3892/etm.2018.5959
   PubMed Web of Science ®Google Scholar
• Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B. 2020;10(11):2156–2170. doi:10.1016/j.apsb.2020.04.004
   PubMed Web of Science ®Google Scholar
• Shu Y, Cheng P. Targeting tumor-associated macrophages for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188434. doi:10.1016/j.bbcan.2020.188434
   PubMed Web of Science ®Google Scholar
• Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol. 2011;714:141–150. doi:10.1007/978-94-007-0782-5_7
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437–442. doi:10.1038/nature19834
   PubMed Web of Science ®Google Scholar
• Huang L, Cheng YY, Chow LT, Zheng MH, Kumta SM. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol. 2003;56(2):116–120. doi:10.1136/mp.56.2.116
   PubMedGoogle Scholar
• Dancsok AR, Gao D, Lee AF, et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340. doi:10.1080/2162402X.2020.1747340
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225–232. doi:10.1016/j.coi.2012.01.010
   PubMed Web of Science ®Google Scholar
• Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPα axis. Front Immunol. 2020;11:18. doi:10.3389/fimmu.2020.00018
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416. doi:10.1038/nrclinonc.2016.217
   PubMed Web of Science ®Google Scholar
• Anfray C, Ummarino A, Andón FT, Allavena P. Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses. Cells. 2019;9(1):46. doi:10.3390/cells9010046
   PubMed Web of Science ®Google Scholar
• Lippens L, Van Bockstal M, De Jaeghere EA, et al. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment. Int J Cancer. 2020;147(2):554–564. doi:10.1002/ijc.32893
   PubMed Web of Science ®Google Scholar
• Shaikh S, Noshirwani A, West N, Perry S, Jayne D. Can macrophages within the microenvironment of locally invasive rectal cancers predict response to radiotherapy? Lancet. 2015;385 Suppl 1:S87. doi:10.1016/S0140-6736(15)60402-0
   PubMed Web of Science ®Google Scholar
• Ou D, Adam J, Garberis I, et al. Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. Radiother Oncol. 2019;130:89–96. doi:10.1016/j.radonc.2018.08.013
   PubMed Web of Science ®Google Scholar
• Ilaslan H, Sundaram M, Unni KK. Vertebral chondroblastoma. Skeletal Radiol. 2003;32(2):66–71. doi:10.1007/s00256-002-0599-4
   PubMed Web of Science ®Google Scholar
• Kim SA, Cho KJ, Park YK, et al. Chondroblastoma of the lumbar spine - A case Report and Review of the literature. Korean J Pathol. 2011;45(5):532. doi:10.4132/KoreanJPathol.2011.45.5.532
   Google Scholar
• Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76. doi:10.1186/s13045-019-0760-3
   PubMed Web of Science ®Google Scholar